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Abstract
The Canadian Vasculitis research network (CanVasc) is composed of physicians from different medical specialties,
including rheumatology and nephrology and researchers with expertise in vasculitis. One of its aims was to develop
recommendations for the diagnosis and management of antineutrophil cytoplasm antibody (ANCA)-associated
vasculitides in Canada. This executive summary features the 19 recommendations and 17 statements addressing
general AAV diagnosis and management, developed by CanVasc group based on a synthesis of existing international
guidelines, other published supporting evidence and expert consensus considering the Canadian healthcare context.
Background
ANCA-associated vasculitides (AAV, including granulo-
matosis with polyangiitis [GPA], microscopic polyangiitis
[MPA] and eosinophilic granulomatosis with polyangiitis
[EGPA]) are potentially life-threatening vasculitides
characterized by inflammation of small-sized blood ves-
sels with resultant ischemic events, hemorrhagic events
or both [1]. Their rarity and the heterogeneous nature of
AAV mean that the management of individual patients
can be extremely challenging and may vary markedly
across different geographical regions and medical disci-
plines. Existing guidelines were initially developed prior to
2010, most have not yet been updated, and did not take
into account the specificities of health care system delivery,
access to services and drug treatments in Canada [2–11].
The Canadian Vasculitis research network (CanVasc)
was created in November 2010 and its core committee
includes physicians of different specialties, though pri-
marily rheumatologists and nephrologists. One of the
first major objectives of CanVasc was the development
of recommendations for the management of patients
with AAV within Canada, based on a synthesis of exist-
ing international guidelines, supporting evidence and ex-
pert consensus of a national Canadian AAV clinical and
research network.
Contexte
Les vascularites associées aux ANCA (les VAA, incluant
la granulomatose avec polyangéite [GPA], la polyangéïte
microscopique [MPA], et la granulomatose éosinophili-
que avec polyangéite [EGPA]) sont des vascularites car-
actérisées par une inflammation de la paroi des
vaisseaux sanguins de petit calibre, aboutissant à des
complications ischémiques ou hémorragiques, et qui
mettent souvent en jeu le pronostic vital. Leur rareté, de
même que leur présentations cliniques variées, rendent
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Table 1 Summary table of the CanVasc recommendations and statements
Recommendation or
statement
Text of the recommendation or statement Evidence level/strengtha
Diagnosis
Statement 1 ANCA testing with ELISA and indirect immunofluorescence methods should
be performed for diagnostic purposes in patients in whom there is clinical
suspicion of a systemic small- and/or medium-sized vessel vasculitis.
Statement 2 Tissue biopsy should be considered in cases of suspected AAV to confirm diagnosis.
Classification of disease severity in AAV
Statement 3 Patients with AAV should have the extent and severity of their disease categorized
as ‘severe’ at the time of diagnosis and in case of subsequent relapse if they have
life- or major organ-threatening manifestations in order to tailor therapy accordingly.
The role of referral centres for vasculitis
Statement 4 Patients with AAV, particularly those with challenging disease, should be managed
at or in collaboration with, a referral centre for vasculitis.
Remission induction for newly-diagnosed disease
Remission induction in severe (organ/life-threatening disease) newly-diagnosed disease
Recommendation 1 We recommend remission induction therapy with a combination of high dose
glucocorticoids and cyclophosphamide in patients with severe newly diagnosed
GPA, MPA or EGPA.
1B/A
Recommendation 2 We recommend using high dose glucocorticoids with rituximab as 1st line
remission induction therapy in patients with severe GPA or MPA in whom
cyclophosphamide is contraindicated or in whom cyclophosphamide presents
an unacceptable risk of infertility.
1B/A
Recommendation 3 Cyclophosphamide dose should be adjusted in patients >60 years of age and in
those with renal impairment.
1B/B
Statement 5 Complete blood count (CBC) and serum creatinine level must be monitored in
patients treated with cyclophosphamide. In patients with abnormal CBC results,
temporary withholding of cyclophosphamide and subsequent dose adjustments
may be necessary depending on the degree of leucopenia.
Recommendation 4 We recommend that the remission induction therapy with cyclophosphamide,
combined with glucocorticoids, lasts a minimum of 3 to a maximum of 6 months.
Once remission is achieved, cyclophosphamide should be stopped and switched to
a different maintenance therapy.
1B/A
Recommendation 5 We recommend that glucocorticoids should be given in adults at an initial dose of
1 mg/kg/day prednisone-equivalent for remission induction purposes. This may be
preceded by pulsed methylprednisolone (0.5–1 g/day for 1–3 days) in patients with
life threatening disease and/or major organ involvement.
2A/B
Recommendation 6 Prophylaxis against Pneumocystis jiroveci infection should be given to patients receiving
cyclophosphamide or rituximab. This prophylaxis consists, in the absence of allergy,
of trimethoprim/sulfamethoxazole compounds (800/160 mg 1 tablet 3 times per week
or 400/80 mg daily).
3/C
Recommendation 7 There is insufficient evidence to support a recommendation that plasma exchange be
used as first line therapy in any AAV patients. Plasma exchange may be a reasonable
adjuvant therapy for patients who clinically deteriorate due to active vasculitis despite
ongoing remission induction therapy with high-dose glucocorticoids and
cyclophosphamide or rituximab.
4/D
Remission induction for limited or non-severe (non organ- and non life-threatening),
newly-diagnosed disease
Recommendation 8 In patients with limited and/or non-severe GPA, which is non-life threatening and
without any major organ involvement, remission induction regime with methotrexate
in combination with glucocorticoids can be used.
1B / A
Recommendation 9 Patients with non-severe EGPA or non-severe MPA without renal involvement can
be treated with glucocorticoids alone for remission induction. At present, there is no
consensus on the use of any immunosuppressant agents in combination with
glucocorticoids in patients with EGPA or MPA that are non-severe (including those
with mononeuritis multiplex).
2B/C
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Table 1 Summary table of the CanVasc recommendations and statements (Continued)
Remission maintenance therapy
Recommendation 10 In patients with severe AAV in remission after a combined cyclophosphamide-
glucocorticoid-based induction treatment, maintenance therapy can be based
on azathioprine or methotrexate, initially in combination with low-dose
glucocorticoids. Leflunomide or mycophenolate may be alternative agents in
patients not tolerating or with contra-indications to azathioprine and methotrexate.
1B/B
Recommendation 11 In patients with severe AAV in remission after a combined cyclophosphamide-
glucocorticoid-based induction treatment, maintenance therapy with rituximab
infusions is an alternative to azathioprine, especially for those patients with
PR3-ANCA-positive GPA.
1B/A
Statement 6 To date there is no definitive evidence to guide decisions for maintenance
therapy after remission induction with rituximab.
Statement 7 Low dose glucocorticoids should be part of the initial remission maintenance
therapy after remission is achieved; there is not enough evidence yet to support
further recommendation on the optimal duration of low dose glucocorticoids.
Recommendation 12 We recommend the use of azathioprine, methotrexate or their alternatives
(as per Recommendation 10 and 11) for remission maintenance therapy to be
continued for a minimum of 18 months after successful remission induction.
There is not enough evidence yet to support further recommendation on the
optimal duration of their use for maintenance.
3/C
Recommendation 13 The use of trimethoprim/sulfamethoxazole (800/160 mg twice daily) as remission
maintenance therapy can be considered in GPA as an adjuvant to immunosuppressant
or after the cessation of maintenance immunosuppressive treatment.
3/C
Recommendation 14 Topical therapies may be considered, in combination with the systemic therapy and




Recommendation 15 We recommend remission induction of a major organ- or life-threatening relapse
with either cyclophosphamide or rituximab in conjunction with high dose
glucocorticoids. In patients who already received cyclophosphamide for initial
remission induction or a previous disease flare, we recommend using rituximab
for remission re-induction.
1B/A
Recommendation 16 There is insufficient evidence to support a recommendation that plasma exchange
be used as first line therapy in all patients with relapsing AAV with severe renal
(GFR <50 ml/min) or pulmonary hemorrhage. Plasma exchange may be a reasonable
adjuvant therapy for patients who clinically deteriorate due to active relapsing vasculitis
despite ongoing remission induction therapy with high-dose glucocorticoids and
cyclophosphamide or rituximab.
4/D
Recommendation 17 We recommend that relapses that are non-severe, i.e. non-life and non-organ threatening,




Recommendation 18 We recommend the use of rituximab, in combination with glucocorticoids, in patients
with severe GPA or MPA who fail to respond to cyclophosphamide as remission
induction therapy.
3/C
Statement 8 Patients with refractory disease should be managed in a referral centre for vasculitis in
collaboration with subspecialists with experience in managing such patients.
Statement 9 Patients with EGPA and persistent asthmatic symptoms, despite remission of their
vasculitic manifestations, should be managed in collaboration with a physician
subspecializing in asthma management.
Additional and experimental therapies
Statement 10 In patients in whom the aforementioned therapies are ineffective, contraindicated or
poorly tolerated, consideration can be given to alternate, additional and/or experimental
therapies in collaboration with a referral centre for vasculitis.
Follow up of patients with AAV
Statement 11 Patients with AAV should be followed regularly for many years with full clinical
assessment and routine laboratory work to assess disease course and track for disease
activity and disease- or treatment-related damage.
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la prise en charge des patients extrêmement ardue, sur-
tout si elle diffère selon les régions géographiques et les
disciplines médicales. Les recommandations internatio-
nales de prise en charge des VAA existantes ont été
développées avant 2010; la plupart n’ont pas encore été
mises à jour et aucune ne tenait compte des spécificités
de prestation des soins, d’accès aux services et aux divers
traitements pharmacologiques dans le réseau de santé
canadien.
Le groupe de recherche canadien sur les vascularites
(CanVasc) a été créé en novembre 2010. Il est constitué
de médecins de diverses spécialités, quoique surtout des
rhumatologues et néphrologues. L’un des objectifs
principaux de CanVasc était l’élaboration de recomman-
dations de prise en charge des patients atteints de VAA
au Canada, en se basant sur les recommandations
internationales déjà existantes, les autres preuves scientifi-
ques et publications dans le domaine des VAA, et un pro-
cessus avec plusieurs étapes afin d’aboutir à un consensus.
Methods
Prior to initiating the development of these recommen-
dations, a national Needs Assessment Questionnaire was
disseminated to identify the specific areas of need, pos-
sible knowledge gaps and outline key questions [12].
The international existing clinical practice guidelines
and consensus statements on the management of AAV
published in English or French between 2006 and May
2014 were then reviewed, in addition to Cochrane library
and PubMed Medline searches for all therapeutic studies
published after the 2009 European League against Rheuma-
tism/European Vasculitis Society (EULAR/EUVAS) recom-
mendations and May 2014. The first draft of these
recommendations was developed by the core group of the
CanVasc recommendation working group and included
37 recommendations, with the rationale behind each of
them, the corresponding recommendations and guid-
ance from other societies, when existing and the level
of evidence categorized and graded according to the
criteria previously endorsed by EULAR/EUVAS [2, 13].
This first draft was reviewed by all members of the
CanVasc recommendation working group (using a
modified Delphi method) with a phone conference held
thereafter to reach consensus on all debated recom-
mendations, especially those not agreed upon by >80 %
of the reviewers. A revised version of recommendations
was then developed and distributed again for review to
the same working group and a broader spectrum of
other reviewers, including members of several profes-
sional medical societies and specialists and the adminis-
trative bureau of the Canadian support group for
vasculitis patients (Vasculitis Foundation Canada). The
Table 1 Summary table of the CanVasc recommendations and statements (Continued)
Statement 12 All patients previously treated with cyclophosphamide should have a urinalysis
every 3–6 months as a lifelong means of screening for cyclophosphamide-induced
bladder toxicity. If micro- or macroscopic hematuria is present, in the absence
of an alternate explanation, the patient should be referred for consideration
of a cystoscopy.
Statement 13 As part of their lifelong annual follow-up, cardiovascular risk factors (including smoking
status, diabetes, hypercholesterolemia, hypertension and obesity) and risk for osteoporosis
should be systematically assessed, with treatment as needed according to the current
respective guidelines for each of these conditions.
Special patient groups
Statement 14 Women with AAV should not consider pregnancy earlier than 6 months after sustained
remission of their disease has been achieved. Women with AAV planning pregnancy and
those pregnant should be managed in close collaboration with an obstetrician with
expertise in this field and/or in high-risk pregnancies.
Statement 15 There are no pediatric specific management guidelines for pediatric AAV, and most
knowledge in pediatric AAV is adapted from adult research. Management of children
with AAV should be provided by pediatric physicians at an academic healthcare Centre,
in collaboration with referral centres for vasculitis and/or centres with special interest in
pediatric vasculitis.
Statement 16 AAV in children should be classified at the time of diagnosis based on the childhood
EULAR/PRINTO/PReS criteria in order to tailor therapy accordingly.
Statement 17 Children with newly diagnosed AAV should be treated according to adult recommendations
for induction of remission and then maintenance, with dose of medications adjusted for
this specific population.
Recommendation 19 In children, severe relapsing AAV or severe AAV refractory to the combination of
cyclophosphamide and glucocorticoids (with major organ involvement or life-threatening
manifestations) should be treated with rituximab, in combination with glucocorticoids.
4/D
aStatements are not related to specific treatments and were not be graded as there was no strong evidence or available studies to support them
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comments were gathered and discussed during a sec-
ond teleconference with the members of the CanVasc
recommendation working group to reach consensus on
the final version of the document, which was endorsed
by the Canadian Rheumatology Association (CRA)
Guidelines Committee on March 21st, 2015.
Results
The final document (the full version of the recommenda-
tions is available online at http://www.jrheum.org) in-
cludes 19 recommendations and 17 statements addressing
general management strategies for AAV, including their
diagnosis, treatments with glucocorticoids, traditional im-
munosuppressants and biologic agents, and follow up for
rheumatologists, nephrologists, respirologists, general in-
ternists, general practitioners and all other health care
professionals more occasionally involved in the manage-
ment of patients with AAV in community and academic
practice settings. Each therapeutic recommendation and
statement is accompanied by supporting text, which re-
ports on the expected health benefits, potential side effects
and risks, and Canadian system factors that may influ-
ence their applicability. Therapeutic recommendations
are presented with a level of evidence and strength
(Table 1 of the executive summary). Statements are for
non-therapeutic recommendations and working group
consensus, for which there is no strong supporting evi-
dence from controlled studies are not graded. For each
recommendation and statement, we also present in the
extended version (available online with the full version
of the recommendations at http://www.jrheum.org)
corresponding recommendations and guidance previ-
ously published on the same topic from other societies,
when available.
Discussion and conclusion
This document will serve as useful knowledge to support
decision-making for any physician involved in the care
of patients with AAV, including adults and children. Best
clinical judgment must however always prevail when
confronted with each specific patient scenario. New
information from ongoing research may already have
become available by the time the present document is
published. Regular updates will thus be mandatory.
Competing interests
Lucy McGeoch, Marinka Twilt, Leilani Famorca, Susan Benseler, David Cabral,
Simon Carette, Christine Dipchand, Michelle Goulet, Majed Khraishi, Nataliya
Milman, Nooshin Samadi, Regina Taylor-Gjevre, Tanveer A. Towheed, Michael
Walsh and Elaine Yacyshyn: These authors declare that they have no
competing interests. Volodko Bakowsky: Fees for serving on advisory boards
from Hoffman-LaRoche. Lillian Barra: Honoraria from Hoffman-LaRoche,
Abbvie, Amgen and UCB (<$5,000). Gerard P. Cox: Fees for serving on
advisory board from Hoffman-LaRoche (2013). Navjot Dhindsa: Honoraria
from Hoffman-LaRoche and Abbvie. Aurore Fifi-Mah: Fees for serving on
advisory boards from Hoffman-LaRoche. Nader Khalidi: Fees for serving on
advisory Boards from Hoffman-LaRoche, Bristol-Myers Squibb, UCB; lecture
fees from Hoffman-LaRoche. Patrick Liang: Honorarium for lectures from
Hoffman-LaRoche, Abbvie, Bristol-Myers Squibb, Janssen, Pfizer; financial
support for clinical project from Hoffman-LaRoche. Christian A. Pineau: Fees
for serving on advisory boards from Hoffman-LaRoche. Heather Reich: Fees
for providing advisory services to Hoffman-LaRoche, AMGEN and Alexion.
Kam Shojania: Lecture and consultation fees from Hoffman-LaRoche
(<$5,000). Judith Trudeau: Fees for serving on advisory boards for Hoffman-
LaRoche and Bristol-Myers Squibb; grant for attending scientific meetings on
vasculitis by Hoffman-LaRoche. Christian Pagnoux: Fees for serving on
advisory boards from Hoffman-La Roche, Genzyme and GlaxoSmithKline;
lecture fees from Roche, Bristol-Myers Squibb and EuroImmune; grant
support from Hoffman-La Roche Roche; coordinator of the 2007 French
Vasculitis Study Group recommendations (Protocole national de diagnostic
et de soins - vascularites nécrosantes systémiques; under the aegis of the
Haute Autorité de Santé).
Authors' contributions
CP organized and led the development of this document; LM, MT and LF
wrote the first draft and edited the second and final draft of this document;
all authors participated in the development of this document in its different
stages (as detailed in the Methods), read and approved the final manuscript.
Acknowledgements
In addition to the authors, the following persons participated in the
development of these recommendations (reviewers): Drs. Corisande Baldwin,
Maria Bagovich, Claire Barber, Joanne Bargman, David Barth, Sankalp Bhavsar,
Ken Blocka, Gilles Boire, Boussier, Robert Ferrari, Michele Hladunewich, Susan
Huang, Jacob Karsh, Kim Legaut, Emil Nashi, Maxime Rhéaume, Nathalie Roy,
Evelyn Sutton, Yves Troyanov, Pearce G. Wilcox; and the Vasculitis
Foundation Canada (Jon Stewart, Katherine Smith and Barbara Tuntoglu,
from the administrative board). Sandra Messier provided administrative
coordination and support and Dr. Shahin Jamal and the CRA therapeutic
committee provided guidance throughout the development of these
recommendations.
Disclosures
The development of these recommendations was entirely self-funded. None of
the authors received any fees, grants or emoluments for the development of
these recommendations. No funding support from pharmaceutical companies
was received; no representatives of pharmaceutical companies were involved at
any step in the development of these recommendations. Potential conflicts
for each working group member including industry funding, consultancies,
commercial interests and direct involvement in any guidelines included in
the systematic review are listed in the Appendices (available online at
http://www.jrheum.org).
Author details
1Department of Rheumatology, Mount Sinai Hospital, University of Toronto
Toronto Ontario, Canada. 2Current address: Centre for Rheumatic Diseases,
Glasgow Royal Infirmary Glasgow UK. 3Division of Pediatric Rheumatology,
Alberta Children’s Hospital, University of Calgary Calgary Alberta, Canada.
4Division of Rheumatology, McMaster University, Hamilton and Langs
Community Centre Cambridge Canada. 5Division of Rheumatology, QEII
Health Sciences Centre and Dalhousie University Halifax Nova Scotia, Canada.
6Division of Rheumatology, St. Joseph’s Health Care London Ontario, Canada.
7Division of Pediatric Rheumatology, BC Children’s Hospital and University of
British Columbia Vancouver British Columbia, Canada. 8Division of
Respirology, McMaster University, St. Joseph’s Healthcare Hamilton Ontario,
Canada. 9Division of Nephrology, Dalhousie University Halifax Nova Scotia.
10Section of Rheumatology, University of Manitoba, Arthritis Centre Winnipeg
Manitoba, Canada. 11University of Calgary Calgary Alberta, Canada. 12Division
of Internal Medicine, Hôpital Du Sacré-Coeur Montréal Québec, Canada.
13Division of Rheumatology, McMaster University Hamilton Ontario, Canada.
14Division of Rheumatology, Memorial University of Newfoundland, Nexus
Clinical Research St. Johns Newfoundland, Canada. 15Division of
Rheumatology, Centre Hospitalier Universitaire de Sherbrooke Québec
Canada. 16Division of Rheumatology, the Ottawa Hospital/University of
Ottawa Ottawa Ontario, Canada. 17Division of Rheumatology, Lupus and
Vasculitis Clinic, McGill University Montréal Québec, Canada. 18Gabor
Zellerman Chair in Nephrology Research of Toronto, Division of Nephrology,
University Health Network Toronto Ontario, Canada. 19Division of
McGeoch et al. Canadian Journal of Kidney Health and Disease  (2015) 2:43 Page 5 of 6
Rheumatology and the Arthritis Program Research Group in Newmarket
Newmarket Ontario, Canada. 20Division of Rheumatology, Arthritis Research
Canada, University of British Columbia Vancouver British Columbia, Canada.
21Division of Rheumatology, University of Saskatchewan Saskatoon
Saskatchewan, Canada. 22Department of Medicine, Queen’s University
Kingston Ontario, Canada. 23Division of Rheumatology, CHAU Hôtel-Dieu de
Lévis, Université Laval Québec Canada. 24Department of Medicine and
Department of Clinical Epidemiology and Biostatistics, McMaster University
Hamilton Ontario, Canada. 25Division of Rheumatology, University of Alberta
Edmonton Alberta.
Received: 20 July 2015 Accepted: 25 July 2015
References
1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised
International Chapel Hill Consensus Conference Nomenclature of
Vasculitides. Arthritis Rheum. 2013;65:1–11.
2. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al.
EULAR recommendations for the management of primary small and
medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–7.
3. Guerry MJ, Brogan P, Bruce IN, D'Cruz DP, Harper L, Luqmani R, et al.
Recommendations for the use of rituximab in anti-neutrophil cytoplasm
antibody-associated vasculitis. Rheumatology (Oxford). 2011;51:634–43.
4. Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D'Cruz D, et al. BSR
and BHPR guidelines for the management of adults with ANCA associated
vasculitis. Rheumatology (Oxford). 2007;46:1615–6.
5. Luxton G, Langham R. The CARI guidelines. ANCA serology in the diagnosis
and management of ANCA-associated renal vasculitis. Nephrology (Carlton).
2008;13 Suppl 2:S17–23.
6. JCS. Guideline for management of vasculitis syndrome (JCS 2008). Japanese
Circulation Society. Circ J. 2008;75:474–503.
7. Menahem S, Hiremagalur B, Mudge D, Toussaint N, Walters G. The CARI
guidelines. Induction and maintenance therapy in ANCA-associated
systemic vasculitis. Nephrology (Carlton). 2008;13 Suppl 2:S24–36.
8. Pagnoux C, FVSG. Vascularites nécrosantes systémiques - Protocole national
de diagnostic et de soins. 2009. www.has-sante.fr.
9. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis
Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis.
Kidney Int. 2012;2(2):139–274.
10. Charles P, Bienvenu B, Bonnotte B, Gobert P, Godmer P, Hachulla E, et al.
Rituximab: Recommendations of the French Vasculitis Study Group (FVSG)
for induction and maintenance treatments of adult, antineutrophil
cytoplasm antibody-associated necrotizing vasculitides. Presse Med.
2013;42:1317–30.
11. Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, et al.
BSR and BHPR guideline for the management of adults with ANCA-
associated vasculitis. Rheumatology (Oxford). 2014;53:2306–9.
12. Famorca L, Twilt M, Barra L, Bakowsky V, Benseler SM, Cabral D, et al.
Development of Canadian recommendations for the management of
ANCA-associated vasculitides: results of the national needs assessment
questionnaire. Open J Rheumatol. 2015. [In press].
13. Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin F,
Hirvonen J, et al. EULAR standardised operating procedures for the
elaboration, evaluation, dissemination, and implementation of
recommendations endorsed by the EULAR standing committees. Ann
Rheum Dis. 2004;63:1172–6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
McGeoch et al. Canadian Journal of Kidney Health and Disease  (2015) 2:43 Page 6 of 6
